These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 21233451)

  • 1. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
    Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.
    Toyoda T; Kamei Y; Kato H; Sugita S; Takeya M; Suganami T; Ogawa Y
    Obesity (Silver Spring); 2008 Jun; 16(6):1199-207. PubMed ID: 18356826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes.
    Kudoh A; Satoh H; Hirai H; Watanabe T
    Life Sci; 2011 Jun; 88(23-24):1055-62. PubMed ID: 21514306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
    Iwai M; Kanno H; Inaba S; Senba I; Sone H; Nakaoka H; Horiuchi M
    Am J Hypertens; 2011 Feb; 24(2):169-74. PubMed ID: 20847723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Carotene accumulation in 3T3-L1 adipocytes inhibits the elevation of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-α.
    Kameji H; Mochizuki K; Miyoshi N; Goda T
    Nutrition; 2010; 26(11-12):1151-6. PubMed ID: 20097535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
    Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.
    Powell LA; Crowe P; Kankara C; McPeake J; McCance DR; Young IS; Trimble ER; McGinty A
    Clin Sci (Lond); 2012 Aug; 123(3):135-46. PubMed ID: 22309242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
    Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid.
    Yamazaki Y; Kawano Y; Uebayasi M
    Life Sci; 2008 Jan; 82(5-6):290-300. PubMed ID: 18166202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
    Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
    Lv Q; Wang Y; Wang W; Wang L; Zhou X
    Endocr Res; 2009; 34(4):130-41. PubMed ID: 19878073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.
    Hansmann G; Wagner RA; Schellong S; Perez VA; Urashima T; Wang L; Sheikh AY; Suen RS; Stewart DJ; Rabinovitch M
    Circulation; 2007 Mar; 115(10):1275-84. PubMed ID: 17339547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
    Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice.
    Mohapatra J; Sharma M; Singh S; Chatterjee A; Swain P; Balaraman R; Patel PR; Jain MR
    Pharmacology; 2009; 84(4):203-10. PubMed ID: 19738399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.